Rise Therapeutics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Solid Tumor, AdultSolid TumorMelanomaBasal Cell CancerSquamous Cell CancerAdenoma
- Interventions
- Drug: R-5780
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 33
- Registration Number
- NCT06398418
R-2487 in Patients With Sjogren's Syndrome (SS)
Phase 1
Not yet recruiting
- Conditions
- SjögrenSjogren's SyndromeSjögren Syndrome, Unspecified
- Interventions
- Drug: R-2487
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06297213
R-5280 in Newly Diagnosed Patients with Type 1 Diabetes
Phase 1
Recruiting
- Conditions
- Type 1 DiabetesType 1 Diabetes (Juvenile Onset)Diabetes Mellitus, Type 1
- Interventions
- Other: PlaceboDrug: R-5280
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 39
- Registration Number
- NCT06057454
- Locations
- 🇺🇸
UTSW Medical Center, Dallas, Texas, United States
🇺🇸Edward Jenner Research Group LLC, Plantation, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
R-2487 in Patients with Rheumatoid Arthritis
Phase 1
Recruiting
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: R-2487
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05961592
- Locations
- 🇺🇸
St.Jude Clinical Research, Doral, Florida, United States
🇺🇸AP Medical Research, Miami, Florida, United States
🇺🇸Altoona Center for Research, Duncansville, Pennsylvania, United States
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Phase 1
Recruiting
- Conditions
- Ulcerative Colitis Chronic MildUlcerative Colitis Chronic ModerateUlcerative Colitis ChronicUlcerative Colitis
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05666960
- Locations
- 🇺🇸
University of Colorado School of Medicine, Aurora, Colorado, United States
🇺🇸AP Medical Research LLC, Miami, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath